• Adocia amended its shareholder current account advance agreement with Vester Finance on October 20, 2026, increasing financing by EUR 4 million to EUR 10 million.
• Advances are repayable at any time in cash or newly issued shares, with share subscriptions subject to a maximum 7% discount.
• A separate capital increase raised EUR 3 million through 1,477,934 new shares priced at EUR 2.04 each.
• The financing package, assuming full use of the advance facility, extends cash runway to the first quarter of 2028 alongside cost reductions.
• A USD 20 million milestone payment conditional on Chinese approval of BioChaperone Lispro could extend cash runway to 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adocia SA published the original content used to generate this news brief on October 20, 2026, and is solely responsible for the information contained therein.